🔎 Trials Near Me

Domov › Rak jajčnikov › Ohio

Klinične študije za Rak jajčnikov v Ohio

70 študij za Rak jajčnikov išče udeležence na lokacijah v Ohio.

Mesta v Ohio

Uradno besedilo študije (angleško)

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

  • OhioHealth O'Bleness Hospital, Athens
  • UH Seidman Cancer Center at UH Avon Health Center, Avon
  • UHHS-Chagrin Highlands Medical Center, Beachwood
  • in še 39
Vključevanje udeležencevFaza 2
Vse starosti · Vsi spoli · Posodobljeno 2. okt. 2026 · NCT05564377

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

  • The Cleveland Clinic Taussig Cancer Center, Cleveland
Vključevanje udeležencevFaza 1/2
Starost 12 in več · Vsi spoli · Posodobljeno 2. okt. 2026 · NCT04585750

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

  • University Hospitals Cleveland Medical Center, Cleveland
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 2. okt. 2026 · NCT06465069

A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

  • Cleveland Clinic - Oncology Department, Cleveland
Vključevanje udeležencevFaza 2
Starost 18 in več · Vsi spoli · Posodobljeno 2. okt. 2026 · NCT06760819

A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies

  • University of Cincinnati Medical Center. /ID# 278925, Cincinnati
  • University Hospitals Cleveland Medical Center /ID# 279601, Cleveland
Vključevanje udeležencevFaza 2
Starost 18 in več · Ženske · Posodobljeno 1. okt. 2026 · NCT07024784

Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Homologous Recombination Deficiency (HRD) Negative Advanced Epithelial Ovarian Cancer

  • Research Site, Cleveland
Vključevanje udeležencevFaza 3
Starost 18 in več · Ženske · Posodobljeno 1. okt. 2026 · NCT07851025

A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer

  • Site 0147 - Trihealth Cancer Institute - Harold and Eugen, Cincinnati
  • Site 0243 - Mark H Zangmeister Cancer Center, Columbus
  • Site 0214-Ohio State University Comprehensive Cancer Center, Hilliard
Vključevanje udeležencevFaza 2
Starost 18 in več · Ženske · Posodobljeno 29. sep. 2026 · NCT05128825

A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

  • Metrohealth Medical Center - Cleveland /ID# 276664, Cleveland
  • Cleveland Clinic - Cleveland /ID# 276133, Cleveland
  • Cleveland Clinic - Cleveland /ID# 278273, Cleveland
  • in še 3
Vključevanje udeležencevFaza 2
Starost 18 in več · Ženske · Posodobljeno 29. sep. 2026 · NCT06890338

Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer

  • Cleveland Clinic, Cleveland
Vključevanje udeležencevOpazovalna študija
Starost 18 in več · Ženske · Posodobljeno 29. sep. 2026 · NCT05051722

Study of AVZO-021 in Patients With Advanced Solid Tumors

  • Avenzo Therapeutics Recruiting Site, Cleveland
Vključevanje udeležencevFaza 1/2
Starost 18 in več · Vsi spoli · Posodobljeno 28. sep. 2026 · NCT05867251

DESTINY-PANTUMOUR04

  • Research Site, Canton
  • Research Site, Maumee
Vključevanje udeležencevOpazovalna študija
Starost 18–130 · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT07124000

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

  • The Ohio State University Comprehensive Cancer Center, Columbus
Vključevanje udeležencevOpazovalna študija
Starost 18 in več · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT04981119

Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers

  • The Ohio State University Wexner Medical Center, Columbus
Vključevanje udeležencevFaza 1/2
Starost 18 in več · Ženske · Posodobljeno 25. sep. 2026 · NCT03564340

A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab

  • The Ohio State University Wexner Medical Center, Columbus
Vključevanje udeležencevFaza 1/2
Starost 18 in več · Ženske · Posodobljeno 24. sep. 2026 · NCT04590326

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

  • Research Site, Cincinnati
  • Research Site, Columbus
Vključevanje udeležencevFaza 2
Starost 18–130 · Vsi spoli · Posodobljeno 23. sep. 2026 · NCT05489211

A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer

  • Jamescare Gynecologic Oncology At Mill Run /ID# 277951, Hilliard
Vključevanje udeležencevFaza 2
Starost 18 in več · Ženske · Posodobljeno 22. sep. 2026 · NCT07059845

A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

  • Miami Valley Hospital South, Centerville
  • University of Cincinnati Medical Center, Cincinnati
  • Oncology Hematology Care Inc, Cincinnati
  • in še 7
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 22. sep. 2026 · NCT07213804

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

  • UH Cleveland Medical Center, Cleveland
Vključevanje udeležencevFaza 1/2
Starost 18 in več · Vsi spoli · Posodobljeno 17. sep. 2026 · NCT07109726

A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)

  • University of Cincinnati Medical Center ( Site 0042), Cincinnati
Vključevanje udeležencevFaza 3
Starost 18 in več · Ženske · Posodobljeno 17. sep. 2026 · NCT07318558

A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

  • Oncology Hematology Care, Inc, Cincinnati
  • The Mark H Zangmeister Cancer Center Ohio, Columbus
  • The Ohio State University Wexner Medical Center Division of Gynecologic Oncology, Hilliard
Vključevanje udeležencevFaza 2
Starost 18–99 · Ženske · Posodobljeno 15. sep. 2026 · NCT07023627

Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

  • Cleveland Clinic Foundation, Cleveland
  • Ohio Health Research Institute, Columbus
  • Miami Valley Hospital South, Dayton
  • in še 1
Vključevanje udeležencevFaza 3
Starost 18 in več · Ženske · Posodobljeno 15. sep. 2026 · NCT07214779

FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC

  • Christ Hospital, Cincinnati
  • Ohio State University, Columbus
Vključevanje udeležencevFaza 1/2
Starost 18 in več · Vsi spoli · Posodobljeno 14. sep. 2026 · NCT06303505

Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial

  • Cleveland Clinic, Cleveland
Vključevanje udeležencevFaza 3
Starost 18 in več · Ženske · Posodobljeno 14. sep. 2026 · NCT04575935

Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

  • The Ohio State University Comprehensive Cancer Center, Hilliard
Vključevanje udeležencevFaza 2
Starost 18 in več · Ženske · Posodobljeno 14. sep. 2026 · NCT06787612

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

  • Cleveland Clinic, Cleveland
  • Toledo Clinic Cancer Center, Toledo
Vključevanje udeležencevOpazovalna študija
Starost 18 in več · Vsi spoli · Posodobljeno 14. sep. 2026 · NCT05059444

Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy

  • Miami Valley Hospital South, Centerville
  • Zangmeister Cancer Center, Columbus
Vključevanje udeležencevFaza 3
Starost 18 in več · Ženske · Posodobljeno 9. sep. 2026 · NCT07225270

A Study of Sofe-M in Participants With Selected Advanced Solid Tumors

  • The Ohio State University (OSU) Wexner Medical Center, Columbus
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 4. sep. 2026 · NCT06400472

A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

  • University of Cincinnati Medical Center ( Site 0090), Cincinnati
  • The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C ( Site 0054), Columbus
Vključevanje udeležencevFaza 3
Starost 18 in več · Ženske · Posodobljeno 3. sep. 2026 · NCT06824467

The Vanguard Study: Testing a New Way to Screen for Cancer

  • Louis Stokes Cleveland VA Medical Center, Cleveland
Vključevanje udeležencevVabljeni zdravi prostovoljci
Starost 45–75 · Vsi spoli · Posodobljeno 2. sep. 2026 · NCT06995898

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

  • Cleveland Clinic, Cleveland
  • OhioHealth Research Institute, Columbus
  • Kettering Health, Kettering
  • in še 1
Vključevanje udeležencevFaza 3
Starost 18 in več · Ženske · Posodobljeno 26. avg. 2026 · NCT05281471

Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors

  • The Ohio State University, Columbus
Vključevanje udeležencevFaza 1
Starost 15 in več · Vsi spoli · Posodobljeno 25. avg. 2026 · NCT06276491

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

  • Cincinnati Children's Hospital Medical Center, Cincinnati
Vključevanje udeležencevFaza 1/2
12 Months – 30 Years · Vsi spoli · Posodobljeno 25. avg. 2026 · NCT04851119

A Phase 1 Study of LNCB74 in Advanced Solid Tumors

  • Cleveland Clinic Taussig Cancer Institute, Cleveland
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 21. avg. 2026 · NCT06774963

Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors

  • Research Site, Columbus
Vključevanje udeležencevFaza 1/2
Starost 18–130 · Vsi spoli · Posodobljeno 21. avg. 2026 · NCT05797168

Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity

  • Ohio State University Comprehensive Cancer Center, Columbus
Vključevanje udeležencevFaza 2/3
Starost 18 in več · Vsi spoli · Posodobljeno 19. avg. 2026 · NCT07001748

A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors

  • Normunity Investigational Site, Maumee
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 18. avg. 2026 · NCT07182149

A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.

  • Ohio State University Wexner Medical Center, Columbus
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 18. avg. 2026 · NCT07470853

Effects of a Probiotic Intervention on the Gut and Vaginal Microbiome in Patients With Advanced or Recurrent Ovarian Cancer Undergoing Treatment With Platinum Chemotherapy

  • Ohio State University Comprehensive Cancer Center, Columbus
Vključevanje udeležencevZgodnja faza 1
Starost 18 in več · Ženske · Posodobljeno 17. avg. 2026 · NCT07144826

Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors

  • The Ohio State University, Columbus
Vključevanje udeležencevFaza 1/2
Starost 18 in več · Vsi spoli · Posodobljeno 13. avg. 2026 · NCT05985655

Vir: ClinicalTrials.gov, podatki pridobljeni 5. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.